Developer docs
API playgroundTry for free, no card

Search company profiles

PhaseBio Pharmaceuticals

Full company profile

uuid0004xk6

Namestring
PhaseBio Pharmaceuticals
Legal namestring
PhaseBio Pharmaceuticals, Inc.
Websiteurl
phasebio.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania (with an additional administrative office in San Diego, California) that develops novel therapies for cardiovascular and cardiopulmonary diseases. The company's lead asset is bentracimab (PB2452), a recombinant human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients experiencing major bleeding or requiring urgent surgery; it is currently in Phase 3 development under FDA Breakthrough Therapy Designation and has demonstrated more than 90% good-or-excellent hemostasis efficacy in interim analysis. The pipeline additionally includes PB6440, an oral highly selective aldosterone synthase inhibitor for treatment-resistant hypertension with an IND submission targeted for the second half of 2022, while pemziviptadil (PB1046), a once-weekly VIP analogue for pulmonary arterial hypertension, was voluntarily discontinued in December 2021 due to COVID-19-related manufacturing and enrollment disruption. The technology foundation is PhaseBio's proprietary elastin-like polypeptide (ELP) platform, which enables less-frequent dosing and improved pharmacokinetics across pipeline programs.

PhaseBio currently generates no product revenue and recorded a net loss of $131.1 million against $41.8 million of cash and cash equivalents at year-end 2021, with R&D expense of $102.1 million. Capital has been sourced through an October 2018 IPO on Nasdaq (ticker PHAS), a March 2021 underwritten public offering of 18.4 million shares at $3.50 per share (approximately $60.2 million net proceeds), a financing and co-development agreement with SFJ Pharmaceuticals (up to $120 million, with $91.3 million funded through December 2021), and an exclusive European licensing deal with Alfasigma S.p.A. ($20 million upfront plus up to $245 million in milestones plus tiered royalties). The company is building a U.S. critical-care focused commercial organization under a newly hired Chief Commercial Officer in preparation for a planned mid-2022 BLA submission, with planned direct hospital-channel distribution in the U.S. and partner-led commercialization in Europe (Alfasigma) and China (SFJ). End customers are hospitals, emergency rooms, trauma centers, and surgical facilities treating patients on ticagrelor who experience major bleeding or require urgent surgery.

Short descriptiontext

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing bentracimab, a first-in-class ticagrelor reversal agent, and PB6440 for resistant hypertension, using its proprietary elastin-like polypeptide (ELP) technology platform to address cardiovascular unmet needs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular therapeutics, antiplatelet reversal agents, biopharmaceutical drug development, pulmonary arterial hypertension, resistant hypertension treatment
Industry3 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cardiovascular Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue (Future)
TypeLicensing Royalties
Description

PhaseBio is a clinical-stage biopharmaceutical company that does not currently generate product revenue. The company is preparing for commercialization of bentracimab, its lead product candidate. The company plans to commercialize bentracimab in the U.S. market upon FDA approval, targeting mid-2022 BLA submission.

phasebio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PhaseBio is a clinical-stage biopharmaceutical company developing novel therapies for cardiovascular and cardiopulmonary diseases. Its lead product candidate, bentracimab (PB2452), is a recombinant human monoclonal antibody Fab fragment intended to reverse the antiplatelet activity of ticagrelor in patients with major bleeding or those needing urgent surgery. Earlier-stage assets include the discontinued pemziviptadil (PB1046) once-weekly VIP analogue for PAH and PB6440, an oral aldosterone synthase inhibitor in development for resistant hypertension.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Bentracimab achieved 135% reduction in platelet inhibition within 5-10 minutes after initiation (P<0.001)
+3 more records
Product overview1 text field

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline centers on three main product candidates: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor currently in Phase 3 development; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for pulmonary arterial hypertension (now discontinued); and PB6440, an oral aldosterone synthase inhibitor for resistant hypertension in pre-clinical development. The proprietary elastin-like polypeptide technology platform enables therapies with improved pharmacokinetics and less frequent dosing. PhaseBio is headquartered in Malvern, PA, and San Diego, CA.

Product and service4 records
1Bentracimab (PB2452)
CategoryCardiovascular Biologic / Reversal Agent
Description

A novel, recombinant, human monoclonal antibody antigen-binding fragment (Fab fragment) designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or requiring surgery, currently in late-stage Phase 3 development with FDA Breakthrough Therapy Designation.

2Pemziviptadil (PB1046)
CategoryCardiopulmonary Biologic
Description

A long-acting vasoactive intestinal peptide (VIP) analogue originally developed using the ELP technology platform for once-weekly subcutaneous treatment of pulmonary arterial hypertension; Phase 2b development voluntarily terminated in December 2021 due to COVID-19 impacts on manufacturing, drug supply, and enrollment.

3PB6440
CategoryCardiovascular Small Molecule
Description

An oral, highly selective aldosterone synthase inhibitor in pre-IND development for treatment-resistant hypertension and potentially other cardio-renal indications; designed to address limited treatment options for patients with resistant hypertension and elevated cardiovascular and renal risks.

4Elastin-Like Polypeptide (ELP) Technology Platform
CategoryDrug Delivery / Half-Life Extension Platform
Description

Proprietary elastin-like polypeptide (ELP) technology platform for developing biologics and peptides with extended half-life, less-frequent dosing, and improved pharmacokinetics; engineered pemziviptadil and drives both internal and partnership-based drug-development opportunities.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Berkshire Sterile Manufacturing
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-03-08
Description

Manufacturing partnership with Berkshire Sterile Manufacturing (Lee, MA) for drug product manufacturing. The completion of drug substance and drug product Process Performance Qualification (PPQ) campaign was announced in March 2022, consisting of multiple commercial scale runs required for validation of bentracimab manufacturing process and demonstration of batch-to-batch consistency at commercial scale.

phasebio.com
2Alfasigma S.p.A
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-17
Description

Exclusive licensing agreement with Alfasigma S.p.A., a privately owned specialty pharmaceutical company focused on commercializing medicines in Europe and other key markets. PhaseBio received $20 million upfront payment and is eligible to receive up to $35 million in pre-revenue regulatory milestones and up to $190 million in sales-based payments. PhaseBio will receive tiered royalties starting in low double digits up to mid-twenties on net sales. This collaboration reinforces the global bentracimab opportunity and establishes accessibility to the largest pool of ticagrelor patients in the world.

phasebio.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-03-01
Description

Commercial scale supply agreement with BioVectra, an innovative global contract development and manufacturing organization (CDMO), for production of bentracimab active pharmaceutical ingredient (API). BioVectra provides integrated CDMO services for manufacturing of bentracimab API for use in Phase 2b and Phase 3 clinical trials and for global commercial supply upon regulatory approval. The partnership includes Windsor, Nova Scotia facility for drug substance manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

SFJ Pharmaceuticals is a financing and co-development partner for bentracimab in the European Union and China. Under the agreement, SFJ agreed to pay up to $120.0 million to support global development of bentracimab, with $90.0 million initial funding plus $30.0 million upon meeting pre-defined clinical milestones. SFJ has provided $91.3 million through December 2021 and is leading clinical development efforts in China. SFJ is also leading the IND application process in China, where the CDE approved the IND application in August 2021.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers5 records
TypeDirect peer
Description

Cardiovascular specialty pharmaceutical company focused on Vascepa (icosapent ethyl) for cardiovascular risk reduction. Comparable as a publicly-traded, single-asset-focused cardiovascular specialty pharma with concentrated revenue dependence and physician-driven commercial model.

TypeDirect peer
Description

Cardiovascular specialty pharmaceutical company developing bempedoic acid (Nexletol) for LDL-cholesterol lowering in statin-intolerant patients. Similar profile as a late-stage commercial-stage cardiovascular specialty company navigating payor and physician adoption.

TypeBroad incumbent
Description

Acquired Portola Pharmaceuticals and now markets AndexXa (andexanet alfa), the first FDA-approved reversal agent for Factor Xa inhibitors. Directly comparable mechanism (antibody-based anticoagulant reversal) and critical-care commercial model make it the closest analog to bentracimab's intended use case.

TypeDirect peer
Description

Developer of AndexXa (andexanet alfa), a biologic reversal agent for Factor Xa anticoagulants. Closest direct analog to bentracimab in mechanism (antibody fragment reversal), regulatory pathway (Breakthrough Designation, accelerated approval), and critical-care commercial model; acquired by Alexion in 2020.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PhaseBio Pharmaceuticals

Cardiovascular Biopharmaceuticalsphasebio.com

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing bentracimab, a first-in-class ticagrelor reversal agent, and PB6440 for resistant hypertension, using its proprietary elastin-like polypeptide (ELP) technology platform to address cardiovascular unmet needs.

What PhaseBio Pharmaceuticals does

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania (with an additional administrative office in San Diego, California) that develops novel therapies for cardiovascular and cardiopulmonary diseases. The company's lead asset is bentracimab (PB2452), a recombinant human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients experiencing major bleeding or requiring urgent surgery; it is currently in Phase 3 development under FDA Breakthrough Therapy Designation and has demonstrated more than 90% good-or-excellent hemostasis efficacy in interim analysis. The pipeline additionally includes PB6440, an oral highly selective aldosterone synthase inhibitor for treatment-resistant hypertension with an IND submission targeted for the second half of 2022, while pemziviptadil (PB1046), a once-weekly VIP analogue for pulmonary arterial hypertension, was voluntarily discontinued in December 2021 due to COVID-19-related manufacturing and enrollment disruption. The technology foundation is PhaseBio's proprietary elastin-like polypeptide (ELP) platform, which enables less-frequent dosing and improved pharmacokinetics across pipeline programs.

PhaseBio currently generates no product revenue and recorded a net loss of $131.1 million against $41.8 million of cash and cash equivalents at year-end 2021, with R&D expense of $102.1 million. Capital has been sourced through an October 2018 IPO on Nasdaq (ticker PHAS), a March 2021 underwritten public offering of 18.4 million shares at $3.50 per share (approximately $60.2 million net proceeds), a financing and co-development agreement with SFJ Pharmaceuticals (up to $120 million, with $91.3 million funded through December 2021), and an exclusive European licensing deal with Alfasigma S.p.A. ($20 million upfront plus up to $245 million in milestones plus tiered royalties). The company is building a U.S. critical-care focused commercial organization under a newly hired Chief Commercial Officer in preparation for a planned mid-2022 BLA submission, with planned direct hospital-channel distribution in the U.S. and partner-led commercialization in Europe (Alfasigma) and China (SFJ). End customers are hospitals, emergency rooms, trauma centers, and surgical facilities treating patients on ticagrelor who experience major bleeding or require urgent surgery.

PhaseBio Pharmaceuticals firmographics

Firmographics
Name
PhaseBio Pharmaceuticals
Legal name
PhaseBio Pharmaceuticals, Inc.
Website
https://phasebio.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing bentracimab, a first-in-class ticagrelor reversal agent, and PB6440 for resistant hypertension, using its proprietary elastin-like polypeptide (ELP) technology platform to address cardiovascular unmet needs.
Ownership category
akta.pro rank

PhaseBio Pharmaceuticals industry classification

Industry
Product category
Cardiovascular Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Cardiovascular therapeutics
  • Antiplatelet reversal agents
  • Biopharmaceutical drug development
  • Pulmonary arterial hypertension
  • Resistant hypertension treatment

Where PhaseBio Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PhaseBio Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Revenue (Future): PhaseBio is a clinical-stage biopharmaceutical company that does not currently generate product revenue. The company is preparing for commercialization of bentracimab, its lead product candidate. The company plans to commercialize bentracimab in the U.S. market upon FDA approval, targeting mid-2022 BLA submission.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

PhaseBio Pharmaceuticals product offering

Product offering

Core offering

PhaseBio is a clinical-stage biopharmaceutical company developing novel therapies for cardiovascular and cardiopulmonary diseases. Its lead product candidate, bentracimab (PB2452), is a recombinant human monoclonal antibody Fab fragment intended to reverse the antiplatelet activity of ticagrelor in patients with major bleeding or those needing urgent surgery. Earlier-stage assets include the discontinued pemziviptadil (PB1046) once-weekly VIP analogue for PAH and PB6440, an oral aldosterone synthase inhibitor in development for resistant hypertension.

Product overview

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline centers on three main product candidates: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor currently in Phase 3 development; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for pulmonary arterial hypertension (now discontinued); and PB6440, an oral aldosterone synthase inhibitor for resistant hypertension in pre-clinical development. The proprietary elastin-like polypeptide technology platform enables therapies with improved pharmacokinetics and less frequent dosing. PhaseBio is headquartered in Malvern, PA, and San Diego, CA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bentracimab (PB2452) A novel, recombinant, human monoclonal antibody antigen-binding fragment (Fab fragment) designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or requiring surgery, currently in late-stage Phase 3 development with FDA Breakthrough Therapy Designation.
  • Pemziviptadil (PB1046) A long-acting vasoactive intestinal peptide (VIP) analogue originally developed using the ELP technology platform for once-weekly subcutaneous treatment of pulmonary arterial hypertension; Phase 2b development voluntarily terminated in December 2021 due to COVID-19 impacts on manufacturing, drug supply, and enrollment.
  • PB6440 An oral, highly selective aldosterone synthase inhibitor in pre-IND development for treatment-resistant hypertension and potentially other cardio-renal indications; designed to address limited treatment options for patients with resistant hypertension and elevated cardiovascular and renal risks.
  • Elastin-Like Polypeptide (ELP) Technology Platform Proprietary elastin-like polypeptide (ELP) technology platform for developing biologics and peptides with extended half-life, less-frequent dosing, and improved pharmacokinetics; engineered pemziviptadil and drives both internal and partnership-based drug-development opportunities.

Quantifiable outcome

  • Bentracimab achieved 135% reduction in platelet inhibition within 5-10 minutes after initiation (P<0.001)
  • +3 more outcomes

Companies that use PhaseBio Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

PhaseBio Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

PhaseBio Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Berkshire Sterile ManufacturingcoreOEM/ Whitelabel/ Licensing Partner · 8 March 2022Manufacturing partnership with Berkshire Sterile Manufacturing (Lee, MA) for drug product manufacturing. The completion of drug substance and drug product Process Performance Qualification (PPQ) campaign was announced in March 2022, consisting of multiple commercial scale runs required for validation of bentracimab manufacturing process and demonstration of batch-to-batch consistency at commercial scale.
  • Alfasigma S.p.AcoreChannel Partner/ Reseller/ Distributor · 17 June 2021Exclusive licensing agreement with Alfasigma S.p.A., a privately owned specialty pharmaceutical company focused on commercializing medicines in Europe and other key markets. PhaseBio received $20 million upfront payment and is eligible to receive up to $35 million in pre-revenue regulatory milestones and up to $190 million in sales-based payments. PhaseBio will receive tiered royalties starting in low double digits up to mid-twenties on net sales. This collaboration reinforces the global bentracimab opportunity and establishes accessibility to the largest pool of ticagrelor patients in the world.
  • BioVectracoreOEM/ Whitelabel/ Licensing Partner · 1 March 2021Commercial scale supply agreement with BioVectra, an innovative global contract development and manufacturing organization (CDMO), for production of bentracimab active pharmaceutical ingredient (API). BioVectra provides integrated CDMO services for manufacturing of bentracimab API for use in Phase 2b and Phase 3 clinical trials and for global commercial supply upon regulatory approval. The partnership includes Windsor, Nova Scotia facility for drug substance manufacturing.
  • SFJ PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2020SFJ Pharmaceuticals is a financing and co-development partner for bentracimab in the European Union and China. Under the agreement, SFJ agreed to pay up to $120.0 million to support global development of bentracimab, with $90.0 million initial funding plus $30.0 million upon meeting pre-defined clinical milestones. SFJ has provided $91.3 million through December 2021 and is leading clinical development efforts in China. SFJ is also leading the IND application process in China, where the CDE approved the IND application in August 2021.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

PhaseBio Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Amarin Corporation: Cardiovascular specialty pharmaceutical company focused on Vascepa (icosapent ethyl) for cardiovascular risk reduction. Comparable as a publicly-traded, single-asset-focused cardiovascular specialty pharma with concentrated revenue dependence and physician-driven commercial model.
  • Esperion Therapeutics: Cardiovascular specialty pharmaceutical company developing bempedoic acid (Nexletol) for LDL-cholesterol lowering in statin-intolerant patients. Similar profile as a late-stage commercial-stage cardiovascular specialty company navigating payor and physician adoption.
  • Portola Pharmaceuticals: Developer of AndexXa (andexanet alfa), a biologic reversal agent for Factor Xa anticoagulants. Closest direct analog to bentracimab in mechanism (antibody fragment reversal), regulatory pathway (Breakthrough Designation, accelerated approval), and critical-care commercial model; acquired by Alexion in 2020.

Peers

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Acquired Portola Pharmaceuticals and now markets AndexXa (andexanet alfa), the first FDA-approved reversal agent for Factor Xa inhibitors. Directly comparable mechanism (antibody-based anticoagulant reversal) and critical-care commercial model make it the closest analog to bentracimab's intended use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

PhaseBio Pharmaceuticals social profiles

Digital presence

PhaseBio Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PhaseBio Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles12 records

PhaseBio Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PhaseBio Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhaseBio Pharmaceuticals

What does PhaseBio Pharmaceuticals do?

PhaseBio is a clinical-stage biopharmaceutical company developing novel therapies for cardiovascular and cardiopulmonary diseases. Its lead product candidate, bentracimab (PB2452), is a recombinant human monoclonal antibody Fab fragment intended to reverse the antiplatelet activity of ticagrelor in patients with major bleeding or those needing urgent surgery. Earlier-stage assets include the discontinued pemziviptadil (PB1046) once-weekly VIP analogue for PAH and PB6440, an oral aldosterone synthase inhibitor in development for resistant hypertension.

Is PhaseBio Pharmaceuticals a public or private company?

PhaseBio Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was PhaseBio Pharmaceuticals founded?

PhaseBio Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is PhaseBio Pharmaceuticals based?

PhaseBio Pharmaceuticals is headquartered in Malvern, United States, in the North America region.

How does PhaseBio Pharmaceuticals make money?

One revenue line is on record: product Revenue (Future).

Who are PhaseBio Pharmaceuticals's main competitors?

Direct peers on record are Amarin Corporation, Esperion Therapeutics and Portola Pharmaceuticals. Corcept Therapeutics is listed as a peer. Alexion (AstraZeneca Rare Disease) is listed as a broad incumbent.

Does PhaseBio Pharmaceuticals have an API?

No public API is recorded for PhaseBio Pharmaceuticals.

What industry is PhaseBio Pharmaceuticals in?

PhaseBio Pharmaceuticals's product category is Cardiovascular Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AJMCTicagrelor Antidote Bentracimab Safely Reverses Antiplatelet Effects in Phase 3 REVERSE-IT TrialPhaseBio Pharmaceuticals and SFJ Pharma presented late-breaking results from the phase 3 REVERSE-IT trial, demonstrating that their investigational antidote bentracimab safely and effectively reverses the antiplatelet effects of ticagrelor. The study showed that 94.3% of patients achieved normal blood clotting within minutes of infusion, with high rates of hemostasis in those undergoing urgent surgery or experiencing major bleeding. These positive findings support the ongoing regulatory assessment for FDA approval, following recent orphan drug designation.Investing.comPhaseBio announces bankruptcy plan confirmation By Investing.comPhaseBio Pharmaceuticals received final court approval for its Chapter 11 bankruptcy plan, which liquidates assets and winds down operations. Priority and secured creditors get full payment, while general unsecured creditors expect about 1.6% recovery, and equity holders receive nothing. The plan terminates 50.2 million shares.American City Business JournalsPhaseBio reaches a deal to transfer its assets to SFJ Pharmaceuticals for $32.9MPhaseBio agreed to transfer its assets to SFJ Pharmaceuticals for $32.9 million. The deal includes all program assets for its new drug candidate in late-stage testing, intended to reverse potentially adverse effects of blood-thinning medicine.GlobeNewswireDelisting of Securities of PhaseBio Pharmaceuticals, Inc.;Nasdaq announced delistings for PhaseBio Pharmaceuticals, Zovio, Fast Radius, and Kismet Acquisition Three, whose stocks were suspended in November 2022 and have not traded since. The delistings will take effect ten days after Nasdaq files Form 25 with the SEC.BenzingaShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.On November 3, 2022, PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) experienced unusual short-selling activity, resulting in the stock price dropping 16.67% to $0.06 per share. The securities lending volatility indicator, produced by Tidal Markets in partnership with Benzinga, showed a volatility change of +59.07% with the current volatility indicator at 14.179, generating a Bearish signal and a Strong Sell recommendation.BenzingaWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket - Argo BlockchaiThis article is a financial market report listing multiple stocks moving in pre-market trading, including gains for Quotient Limited and PhaseBio Pharmaceuticals, and declines for Varonis Systems and The Goodyear Tire & Rubber Company. The data covers various corporate events such as earnings reports, reverse stock splits, and delisting notices affecting these specific entities. The content aggregates disparate market movements rather than focusing on a single cohesive narrative or event.Endpoints NewsAs top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bidPhaseBio has filed for Chapter 11 bankruptcy protection and submitted a stalking-horse bid in response to SFJ Pharmaceuticals' attempt to acquire its lead blood drug. This strategic move by PhaseBio's management aims to counter the pressure from its top investor, SFJ Pharmaceuticals, as the company faces operational struggles.BenzingaPhaseBio Might Have To Return Global Rights To Its Lead ProgramPhaseBio Pharmaceuticals received notice that its co-development partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ after PhaseBio failed to remedy its Going Concern Condition. The company had received acquisition offers for the drug candidate but could not proceed due to SFJ requiring PhaseBio to refrain from terminating the agreement and asserting accelerated termination payment obligations. PhaseBio shares dropped 47.37% in pre-market trading following the announcement.BioSpacePhaseBio Pharmaceuticals Announces Bentracimab Manufacturing UpdatePhaseBio Pharmaceuticals completed the bentracimab drug substance and drug product Process Performance Qualification (PPQ) campaign. The company plans to submit the Biologics License Application (BLA) to the FDA in mid-2022. The PPQ batches will form the basis of the CMC sections of the BLA.BenzingaPhaseBio Pulls Plug On Mid-Stage Hypertension AssetPhaseBio Pharmaceuticals Inc announced the voluntary termination of its Phase 2b trial of pemziviptadil (PB1046) for pulmonary arterial hypertension, citing COVID-19-related disruptions to manufacturing, drug supply, and patient enrollment. The trial had enrolled more than 50% of its target population before the company decided to reprioritize resources toward pre-commercialization of bentracimab and other pipeline programs. The company will analyze the trial data to determine an appropriate path forward for the pemziviptadil program.